Actos® Lawsuit Update: Judge Denies Takeda’s Motion to Overturn $9 Billion Jury Verdict in First MDL Actos® Trial
Bloomberg reports that The Honorable Judge Rebecca Doherty has ruled against Defendants Takeda Pharmaceutical Co. and Eli Lilly in their motion to overturn the $9 Billion verdict decided by a jury earlier this year. In particular, Judge Doherty ruled that jurors properly considered evidence showing that the officials for the manufacturers of Actos® were aware of its link to bladder cancer and failed to adequately warn both patients and doctors of the risk in assessing the damages. The jury verdict is the second-largest in the U.S. in 2014, according to data compiled by Bloomberg.
Judge Doherty presided over the first Actos® trial in the MDL, In re: Actos® (Pioglitazone) Products Liability Litigation (MDL 2299), which concluded on April 7th where the jury awarded the plaintiff $1.5 million in compensatory damages and $9 billion in punitive damages ($6 billion against Takeda; $3 billion against Eli Lilly). The first federal trial in the MDL was Allen v. Takeda Pharmaceuticals North America Inc., Case No. 12-cv-00064, U.S. District Court, Western District of Louisiana (Lafayette).
Actos® is a medication prescribed to control glucose (blood sugar) in adults with Type 2 diabetes. The Food and Drug Administration (“FDA”) approved Actos® in 1999. The drug subsequently became the world’s best-selling diabetes treatment with Actos® sales peaking between March 2010 and March 2011 at $4.5 billion, or 27 percent of Takeda revenue, according to data compiled by Bloomberg News. In June 2011, the FDA issued a Drug Safety Alert warning that the use of Actos® for more than one year may be associated with an increased risk of bladder cancer. According to Bloomberg, Actos® has generated more than $16 billion in sales since its 1999 release.
According to the most recent report issued by the Judicial Panel on Multidistrict Litigation, there are over 3,600 federal Actos® cases pending in MDL 2299. In addition to the Multidistrict Litigation (MDL 2299) pending in federal court, there is also a consolidated state court litigation pending in Cook County Circuit Court in Chicago, Illinois. There are over 3,000 Actos® bladder cancer cases currently on file against Takeda Pharmaceuticals in Cook County before The Honorable Judge Deborah Mary Dooling (In re Actos® Litigation, Case No. 2011 L 10011). The first trial in the Cook County Actos® litigation is scheduled to begin next year.
Schlichter, Bogard & Denton, LLP is a unique law firm that aggressively represents its clients injured as a result of dangerous pharmaceutical medications and unsafe medical devices. If you or a loved one developed bladder cancer after taking Actos® for more than one year, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.
The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.